March 31st, 2025 “EURETINA-Brief”© Issue No. 313
Dear EURETINA Members, A very warm welcome to the March 31st, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
March 31st, 2025
Latest News
March 31st, 2025 “EURETINA-Brief”© Issue No. 313
Dear EURETINA Members, A very warm welcome to the March 31st, 2025 edition of EURETINA’s…
A specific form of macular degeneration (MD) has uncovered three novel genetic variants encoding an adaptor protein (AP-5) complex, essential for macular function.
Researchers at the Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland, and the Centre…
EMA launches a new clinical trial map aimed at increasing access to clinical research studies in the European Union (EU).
EMA (European Medicines Authority) officials have launched a new clinical trial map aimed to provide…
Opthea Ltd (ASX/NASDAQ: OPT) have announced summary Phase 3 results for OPT-302 (sozinibercept) for wet AMD, following suspending shares at the Australian and NASDAQ exchanges.
Opthea Limited (ASX/NASDAQ: OPT), based in Melbourne, Australia and Princeton, New Jersey, have announced summary…